Up to two research calls per year
Research grants
Currently, the majority of our funding is awarded via research grants to academic institutions, although consortia including industry are welcome to apply.
Usually, two scheduled calls for research proposals are held each year. They can either be ‘All priorities’ calls which means that project topics should fit within one or more of EB Resnet’s four strategic research priorities. Alternatively, a scheduled ‘Special’ call may be issued to invite proposals to address identified important unmet research questions, technology needs or clinical consequences arising from EB (e.g. chronic inflammation and fibrosis).
Project scope 'Research grants'
- Fundamental to preclinical research, and clinical trials projects in EB
- Research projects must fall into the scope of a current research call: either an 'All priorities' call or a 'Special call' i.e. chronic inflammation and fibrosis
- Lead applicant: researchers and/or clinicians (cooperation with industry welcome and possible)
- Project duration: 6 to 36 months
- Funding: up to EUR 90,000.00 p.a.
The essential purpose of the grant is to support a single research project in the field of Epidermolysis Bullosa (EB acquisita is excluded) – a piece of work designed to answer a single question or a small group of related questions.
Current & upcoming Calls
The All Priorities Call 2021 closed on 13 September 2021. The deadline for submissions and details on scope are found under closed call.
As soon as there are details about a next call, you will find all information and deadlines here.
Funded projects (EB-ResNet & DEBRA International research calls)
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| All Priorities 2020 | Prof. Alain Hovnanian | INSERM, Paris, France | 1 year | Fundamental research Cellular and molecular therapy | Dystrophic | DEBRA France |
| All Priorities 2020 | Dr. Nicholas Veldhuis | Monash Institute of Pharmaceutical Sciences, Monash University, Australia | 3 years | Symptom relief | Dystrophic | DEBRA Austria |
| All Priorities 2020 | Prof. Eli Sprecher | Tel Aviv Sourasky Medical Center, Israel | 3 years | Fundamental research EB Genetics | all types | DEBRA Austria |
All Priorities 2020 national funding | Dr. Ignacia Fuentes | Clínica Alemana-Universidad del Desarrollo, Chile | 1,5 years | Fundamental research Woundhealing | all types | DEBRA France & DEBRA Austria |
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| CIF Call 2018 | Prof. Giovanna Zambruno | Bambino Gesu Ospedale, Italy | 3 years | Clinical research RNA-therapy Fibrosis | Dystrophic
| DEBRA Austria DEBRA UK DEBRA Spain |
| CIF Call 2018 | Prof. Ulrich Rodeck taken over by Prof. Andy South | Thomas Jefferson University, USA | 2 years | Clinical research Small molecules Fibrosis | Dystrophic | DEBRA Austria DEBRA Ireland |
| CIF Call 2018 | Dr. Yanling Liao | New York Medical College, USA | 3 years | Clinical research Cancer | Dystrophic | DEBRA UK DEBRA Ireland |
| All Priorities 2019 | Prof. Valerie Brunton | University of Edinburgh, UK | 3 years | Fundamental research Cancer | Kindler | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof. Karine Raymond | Leiden University Medical Center, The Netherlands | 3 years | Fundamental research Pluripotent stem cells | Simplex | DEBRA Austria |
| All Priorities 2019 | Dr. Colin Butler | University College London, Great Ormond Street Institute of Child Health, UK | 2 years | Fundamental research Cellular and molecular therapy | Junctional | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof. Liam Grover | University of Birmingham, UK | 2 years | Preclinical research Small molecules | Dystrophic | DEBRA UK DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
Innovative Research Grant Call 2017 | Dr. Cédric Gaggioli | Association pour le Développement des Sciences Médicales, Faculté de Médicine, France | 1 year | Fundamental research Small molecules | Dystrophic | DEBRA Austria |
All Priorities Call 2018 | Prof. Jouni Uitto | Thomas Jefferson University, Philadelphia USA | 2 years | Fundamental research Molecular diagnostics | Dystrophic Junctional Simplex | DEBRA Austria |
All Priorities Call 2018 | Prof. Ganna Bilousova | University of Colorado, USA | 3 years | Fundamental research Cellular and molecular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2018 | Dr. Su Lwin | Kings College London, UK | 2 years | Gene therapy SSC | Dystrophic | DEBRA UK |
All Priorities Call 2018 | Prof. Gareth Inman | University of Glasgow | 1 year | SSC | Dystrophic | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2017 | Prof. Cristina Has | University of Freiburg, Germany | 1 year | Fundamental research Genetics | Simplex | DEBRA Austria |
All Priorities Call 2017 | Dr. Antonia Reimer | University of Freiburg, Germany | 3 years | Fundamental research Clinical characterization | Dystrophic Junctional | DEBRA Austria |
Innovative Research Grant Call 2017 | Prof. Margarita Calvo | Pontificia Universidad Católica de Chile, Chile | 1,5 years | Fundamental research Small molecules Symptom relief | Dystrophic | DEBRA Austria
|
All Priorities Call 2017 | Prof. Daniele Castiglia | IRCCS, Rome, Italy | 3 years | Fundamental research Small molecules Woundhealing | Dystrophic | DEBRA Austria DEBRA UK |
All Priorities Call 2017 | Prof. Thomas Magin | University of Leipzig, Germany | 3 years | Fundamental research Small molecules | Simplex | DEBRA Austria |
All Priorities Call 2017 | Prof. Alain Hovnanian | INSERM, Departement of Genetics, France | 2 years | Fundamental research Cellular and molecular therapy | Dystrophic | DEBRA Austria |
Clinical Call 2015 | Prof. Peter Marinkovich | Stanford University, USA | 3 years | Clinical trial Phase II Cellular and molecular therapy | Dystrophic | DEBRA Austria |
Wound Healing Call 2017 | Initiated by Professor Marcel Jonkman, Nicholas Schräder, and Professor André P. Wolff | University Medical Center Groningen | 3 years | Symptom prevention & relief | all types | DEBRA UK |
Wound Healing Call 2017 | Prof. Dr. Sabine Eming | University Hospital of Cologne, Germany | 3 years | Wound healing, symptom relief | Dystrophic | DEBRA UK, DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2016 | Dr. Fernando Larcher | CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas Prospósito, SPAIN | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof. Arnoud Sonnenberg | Netherlands Cancer Institute, THE NETHERLANDS | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof. Jouni Uitto | Thomas Jefferson University, Philadelphia, USA | 2 years | EB genetics, epigenetics & biology | Simplex Dystrophic Junctional |
DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2015 | Dr. Andrew South | Thomas Jefferson University, Philardelphia, USA | 2 years | Molecular therapy, cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2015 | Dr. Marius Wernig | Standord University, California, USA | 3 years | Molecular therapy | Dystrophic | DEBRA Austria |
Clinical Call 2015 | Prof. Leena Bruckner- Tuderman | University of Freiburg Medical Center, Departement of Determatology, GERMANY | 4 years | Clinical trial Phase II | Dystrophic | DEBRA Austria |
Clinical Call 2015 | Dr. Andrew South, Prof. Johann Bauer, Prof. Jemima Mellerio | Thomas Jefferson University, Philadelphia, US, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK | Start date 1.4.2017 | SCC, Clinical trail Phase II | Dystrophic | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2014-06 | Prof. Mitchell Cairo | New York Medical College, New York, USA | 2 years (+ 1) | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2014-06 | Prof. Crstina Has | University of Freiburg Medical Center, Departement of Dermatology, GERMANY | 2 years | EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
All Priorities Call 2014-12 | Dr. Mark Saville | Ninewells Hospital and Medical School, University of Dundee, UK | 3 years | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2014-12 | Prof. Leena Bruckner-Tuderman | University of Freiburg Medical Center, Germany | Extension | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2013-06 | Dr. Iris Gratz | University of Salzburg, Departement of Molecular Biology, AUSTRIA | 2 years | Molecular therapy, cellular therapy, immunology | Dystrophic | DEBRA Austria |
All Priorities Call 2013-06 | Prof. John McGrath | King’s College London, UK | Extension | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
3MEuro Call 2012 | Prof. Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Determatology, GERMANY | 2 years | Mesenchymal Stromal Cell Therapy | Dystrophic | DEBRA Austria |
3MEuro Call 2012 | Prof. Ellen Brigitte Lane | IMB - Institute of Medical Biology, SINGAPORE | 2 years | EB biology | Simplex, Dowling Meara | DEBRA Austria |
3MEuro Call 2012 | Prof. Peter Marinkovich | Stanford University, California, USA | 3 years | Protein therapy | Dystrophic |
DEBRA Austria |
3MEuro Call 2012 | Dr. Waseem Qasim | Molecular Immunology Unit UCL Institute of Child Health, London, UK | 3 years | Cellular therapy | Dystrophic | DEBRA Austria |
3MEuro Call 2012 | Prof. Dennis Roop | University of Colorade, Denver, USA | 3 years | Stem cell therapy | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2011 | Prof. Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Dermatology, GERMANY | 3 years+1 | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2011 | Prof. Johann Bauer | PMU, Salzburg, AUSTRIA | 3 years | Molecular therapy, cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2011 | Prof. Mitchell Cairo | New York Medical College, New York, USA | 2 years +1 | Molecular therapy, cellular therapy | Dystrophic |
DEBRA Austria |
All Priorities Call 2011 | Prof. Ellen Brigitte Lane | IMB - Institute of Medical Biology, SINGAPORE | 3 years | Molecular therapy | Simplex | DEBRA Austria |
All Priorities Call 2011 | Dr. Derry Charles Roopenian | The Jackson Laboratory, Bar Harbor, Main, USA | 1 year | EB genetics, epigenetics & biology | Junctional | DEBRA Austria |
All Priorities Call 2011-06 | Prof. Johan McGrath | Guy's and St Thomas NHS Foundation Trust, UK | 2,5 years | Molecular therapy | all types | DEBRA UK |
All Priorities Call 2011-06 | Arnoud Sonnenberg | The Netherlands Cancer Institute (NKI), The Netherlands | 2 years | Cellular therapy | Kindler | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2010 | Dr. Cedric Gaggioli | A.D.S.M. Association pour le Développment des Sciences Médicales, Faculté de Médicine, Nice, FRANCE | 1 year | SCC | Dystrophic | DEBRA Austria |
All Priorities Call 2010 | Prof. John McGrath | King's College London, School of Medicine, St. John's Institute of Dermatology, UK | 2 years + 9 months | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2010 | Dr. Alessandra Recchia | Centre fro regenerative Medicine, University of Modena and Reggio Emilia, ITALY | 2 years | Molecular therapy, cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2010 | Prof. Dennis Roop | University of Colorado, Denver, USA | 2 years | iPSC | Simplex |
DEBRA Austria |
All Priorities Call 2010 | Prof. John Sundberg | The Jackson Laboratory, Bar Harbor, USA | 4 months | Junctional | DEBRA Austria | |
All Priorities Call 2010 | Dr. Jakub Tolar | University of Minnesota, Departement of Pediatric Hermatology - Oncology / Blood and bone Marrow Transplantation, USA | 2 years | Cord Blood, Bone marrow | Dystrophic | DEBRA Austria |
All Priorities Call 2010-06 | Prof. W. H. Irwin McLean | University of Dundee, Division of Molecular Medicine, Epithelial Genetics Groupe UK | 3 years | Preclinical study | Simplex | DEBRA UK |
All Priorities Call 2010-06 | Prof. Edel Ann O’Toole | Queen Mary University of London, Centre for Cell Biology and Cutaneous Research UK | 4,5 years | SCC | Dystrophic | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2009 | Prof. Mitchell Cairo | Columbia University, Departement of Medicine and Pathology, New York, USA | 1 year | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2009 | Dr. Laurent Gagnoux-Palacios | A.D.S.M. Association pour le Développement des Sciences Médiacles, Faculté de Médicine, Nice, FRANCE | 3 years | SCC | Junctional | DEBRA Austria |
All Priorities Call 2009 | Prof. Josef Penninger | IMBA Institute of Molecular Biotechnology, Vienna, Austria | 2 years + 6 months | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2009 | Prof. Colin Johada | Durham University, School of Biological and Biomedical Sciences, Durham, UK | 2 years | Dystrophic |
DEBRA Austria | |
All Priorities Call 2009 | Dr. John F. Marshall | Queen Mary University of London, Barts and London Medical School, Institute of Cancer, Centre for Tumour Biology, London, UK | 2 years | SCC | Dystrophic | DEBRA Austria |
All Priorities Call 2009 | Dr. Andrew South | Ninewells Hospital and Medical School, Centre for Oncology and Molecular Medicine, Dundee, UK | 1 year | SCC | Dystrophic | DEBRA Austria |
All Priorities Call 2009 | Dr. Wensin Wang | NUIG National University of Ireland, Galway, Department of Mechanical and Biomedical Engineering, Galway, IRELAND | 1,5 years | Wound healing | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2007 | Prof. Peter Marinkovich | Stanford University, California, USA | 1 year | SCC, Molecular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2007 | Dr. Olga Igoucheva | Jefferson Medical College, Departement of Dermatology and Cutaneous Biology, hiladelphia, USA | 2 years | Cellular therapy | Dystrophic | DEBRA Austria |
